Artelo Biosciences Regains Nasdaq Compliance

Artelo Biosciences has regained compliance with Nasdaq’s continued listing standards.

Rhea-AI Filing Summary

Artelo Biosciences has regained compliance with Nasdaq’s continued listing standards. Nasdaq confirmed the company now meets Listing Rule 5550(b)(1), known as the Equity Rule, and Listing Rule 5620(a), the Annual Shareholders Meeting Rule. Nasdaq will monitor Artelo for one year under a mandatory panel monitor.

The company highlights continued progress across its pipeline, including ART27.13, which showed encouraging Phase 2 CAReS interim data in cancer anorexia-cachexia syndrome and is also being studied in glaucoma, and ART26.12, a non-opioid candidate for neuropathic pain. Management believes this positions Artelo to pursue long-term shareholder value.

Insights

Biotech equity analyst

Nasdaq compliance is restored while Artelo advances multiple mid-stage drug programs.

Artelo’s return to full Nasdaq compliance removes an overhang related to listing risk, which can affect liquidity and institutional access. Compliance with the Equity Rule and Annual Shareholders Meeting Rule indicates it has met minimum equity and governance standards again.

The update also underscores pipeline activity. ART27.13 has encouraging interim Phase 2 data in cancer anorexia-cachexia syndrome and is in another Phase 2 study for glaucoma. ART26.12 is progressing as a non-opioid option for neuropathic pain. Future value will depend on additional clinical data and any partnership progress mentioned around ART27.13.

Key Figures

Monitoring period: one year

1 metrics

Monitoring period one year Mandatory panel monitor under Nasdaq Listing Rule 5815(d)(4)(B)

Key Terms

Nasdaq Listing Rule 5550(b)(1), Equity Rule, Annual Shareholders Meeting Rule, mandatory panel monitor, +2 more

6 terms

Nasdaq Listing Rule 5550(b)(1) regulatory

"confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), the “Equity Rule,”"

Equity Rule regulatory

"Listing Rule 5550(b)(1), the “Equity Rule,” and Listing Rule 5620(a)"

Annual Shareholders Meeting Rule regulatory

"Listing Rule 5620(a), the “Annual Shareholders Meeting Rule.”"

mandatory panel monitor regulatory

"the Company will be subject to a mandatory panel monitor for a period of one year"

A mandatory panel monitor is an independent group tasked with regularly reviewing safety and key results during a clinical trial or regulated program to protect participants and ensure the study is conducted properly. For investors, this matters because the panel can recommend changes, pauses, or early stopping of a trial — actions that can speed up, delay, or quietly derail a program and therefore materially affect a company’s timeline and value, much like a referee whose calls change the outcome of a game.

Phase 2 CAReS interim data financial

"Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects"

neuropathic pain medical

"ART26.12 is advancing as a non-opioid and non-scheduled drug for the treatment of neuropathic pain."

Neuropathic pain is chronic pain caused by damage or dysfunction in the nerves, often described as burning, tingling, electric shocks or numbness rather than pain from injury. It matters to investors because it represents a large, persistent patient population and a tough-to-treat condition where successful therapies, devices or diagnostics can generate steady demand, premium pricing and regulatory attention; think of it like faulty wiring in a house that causes random shocks and needs specialized fixes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Artelo Biosciences (ARTL) announce about its Nasdaq listing?

Artelo Biosciences announced it has regained full compliance with Nasdaq listing requirements. Nasdaq confirmed the company now satisfies Listing Rule 5550(b)(1), the Equity Rule, and Rule 5620(a) on holding an annual shareholders meeting, removing the immediate risk of delisting from the exchange.

Which specific Nasdaq listing rules does Artelo Biosciences (ARTL) now meet?

Artelo now meets Nasdaq Listing Rules 5550(b)(1) and 5620(a). Rule 5550(b)(1), the Equity Rule, relates to minimum stockholders’ equity, while Rule 5620(a) covers the requirement to hold an annual shareholders meeting, both necessary for continued listing on the Nasdaq Capital Market.

Will Artelo Biosciences (ARTL) face any ongoing Nasdaq oversight after regaining compliance?

Yes, Artelo will be under a mandatory panel monitor for one year. Under Nasdaq Listing Rule 5815(d)(4)(B), the company will be monitored for a 12‑month period following the compliance letter, providing additional oversight of its adherence to applicable listing standards.

What pipeline programs did Artelo Biosciences (ARTL) highlight in this update?

Artelo highlighted ART27.13 and ART26.12 as key clinical programs. ART27.13 showed encouraging Phase 2 CAReS interim data in cancer anorexia-cachexia syndrome and is being studied in glaucoma, while ART26.12 is advancing as a non-opioid candidate for treating neuropathic pain.

How does Artelo Biosciences (ARTL) describe its strategic focus going forward?

Artelo emphasizes disciplined, capital-efficient development in high-value indications. Management stated it is focused on advancing its diversified pipeline, progressing potential partnership negotiations for ART27.13, and positioning the company to unlock meaningful long-term value for shareholders through rigorous scientific and commercial execution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 08:00 AM Learn about SEC filing dates

EXHIBIT 99.1

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a)

SOLANA BEACH, Calif., April 7, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), the “Equity Rule,” and Listing Rule 5620(a), the “Annual Shareholders Meeting Rule.”

Nasdaq further confirmed that, based on the Company’s Form 8-K filed January 30, 2026, the Company held its reconvened annual meeting on that date and, based on the Company’s Form 8-K filed March 30, 2026, the Company regained compliance with the Equity Rule. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor for a period of one year from the date of the letter.

“We are pleased to have regained compliance with Nasdaq’s continued listing requirements,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome.”

ART27.13 is also under investigation in an externally funded Phase 2 study as an orally administered agent for the treatment of glaucoma. Artelo’s second clinical stage investigational drug and the first product candidate derived from our FABP5 inhibitor platform, ART26.12 is advancing as a non-opioid and non-scheduled drug for the treatment of neuropathic pain.

“As we continue to advance our pipeline with a focus on high-value indications and capital-efficient development, we believe Artelo is well-positioned to unlock meaningful long-term value for shareholders,” added Gorgas

About Artelo Biosciences  

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, inflammation, and diseases of the eye. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial, discipline to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company's plans and expectations. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements, including market and other conditions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: the use of proceeds from the offering and the potential exercise of the warrants. For a discussion of risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. The Company undertakes no obligation to publicly update any forward-looking statement, except as required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: 

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 PRESS RELEASE 7.4 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.8 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.4 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB